

CLAIMS

1. A method for inhibition of angiogenesis in a tissue expressing the $\alpha 6 \beta 4$ integrin, comprising the steps of exposing the tissue to a therapeutic agent effective to reduce the amount of active $\alpha 6 \beta 4$ integrin in the tissue.
2. The method of claim 1, wherein the tissue is present in a living organism.
3. The method of claim 1, wherein the living organism is human.
4. The method of claim 1, wherein the angiogenesis to be inhibited is pathological angiogenesis.
5. The method of any of claims 1 to 4, wherein the therapeutic agent is an antibody.
6. The method of any of claims 1 to 4, wherein the therapeutic agent is an RNAi species.
7. A method for treatment of a disease condition associated with pathological angiogenesis in a patient, comprising the step of administering to the patient an amount of a therapeutic agent effective to reduce the amount of active $\alpha 6 \beta 4$ integrin.
8. The method of claim 7 wherein the patient is human.
9. The method of claim 7 or 8, wherein the therapeutic agent is an antibody.
10. The method of claim 7 or 8, wherein the therapeutic agent is an RNAi species.

11. Use of an inhibitor of $\alpha 6 \beta 4$ integrin in the preparation of a pharmaceutical composition for inhibition of angiogenesis.
12. Use of claim 11, wherein the angiogenesis is pathological angiogenesis.
13. Use of claim 11 or 12, wherein wherein the therapeutic agent is an antibody.
14. Use of claim 11 or 12, wherein the therapeutic agent is an RNAi species.